If you are not happy with the results below please do another search
HCP satisfaction with biopharma digital offerings is slowly increasing. That’s the good news. The bad news? More than half of HCPs remain dissatisfied or neutral with pharma’s digital offerings. There is room for improvement. Omnichannel engagement (OCE) can help.
Vanda Pharmaceuticals has prevailed in its case against the FDA. On Monday, a federal court sided in favor of Vanda in its Freedom of Information Act case against the agency regarding its sleep drug label expansion.
In an earnings call, bluebird bio revealed it is unlikely to meet its first-quarter goal to submit a Biologics License Application for sickle cell disease (SCD) gene therapy lovo-cel.
The recognition highlights the company’s leadership in artificial intelligence-assisted video production to develop a series of educational content videos to support a client’s need.
This exclusive licence agreement gives GSK rights to commercialize Brexafemme for vulvovaginal candidiasis and recurrent VVC while continuing to develop ibrexafungerp, which is in phase III clinical trials for the potential treatment of invasive candidiasis (IC), a life-threatening fungal infection.
Should they be used broadly, along with diet and exercise? Or should higher risk patients with other conditions be prioritized?
Fears of large litigation bills have since wiped 70% off Philips’ market value.
The company has signed deals with three companies allowing them to make inexpensive generic versions of its long-acting HIV preventive medicine for use in lower-income countries, where the majority of new HIV cases occur.
Patients discontinuing the use of weight-loss drugs such as Wegovy risk regaining their original body weight in about five years, a company official said on Wednesday.
In both assignments, CMI Media Group will handle the companies’ US DTC and HCP omnichannel media planning and buying. The agency is tasked with developing media plans targeting both doctors and patients/consumers.